Hypometabolism-Inducing Agents for Muscular Atrophy Models

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for inducing muscular atrophy, such as denervation and hindlimb suspension, and treatments like dexamethasone, are limited in their effectiveness and scope, and there is a need for alternative approaches to model muscular atrophy and treat muscular hypertrophy and facial muscle shrinkage.

Innovation Solution

A muscular atrophy-inducing agent containing 3-iodothyronamine (T1AM), [D-Ala2,D-Leu5] enkephalin, 5′-adenosine monophosphate, or hydrogen sulfide is used to create a novel study model for muscular atrophy and treat muscular hypertrophy and facial muscle shrinkage by targeting animal and cell models, activating muscle protein degradation pathways while inhibiting synthesis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If conventional methods like dexamethasone or oxidizing substances are used to induce muscular atrophy, then muscle protein degradation is activated, but the treatment lacks versatility for different types of muscular hypertrophy and atrophy models

Engineering Contradiction:

Improveversatility for different muscular hypertrophy typesVSAvoideffectiveness in inducing muscular atrophy

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent employs multiple hypometabolism-inducing substances (T1AM, DADLE, 5'-AMP, H2S) that can induce muscular atrophy through different mechanisms, making the treatment versatile for various types of muscular hypertrophy including myostatin-related, myotonia congenita, and calf hypertrophy, while maintaining reliable atrophy induction effects

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If denervation or hindlimb suspension methods are used to create animal models, then muscular atrophy is effectively induced, but the complexity and invasiveness of the procedures increase

Engineering Contradiction:

Improveeffectiveness in inducing muscular atrophyVSAvoidcomplexity of induction procedure

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent replaces complex mechanical procedures like denervation and hindlimb suspension with chemical administration of hypometabolism-inducing substances, achieving reliable muscular atrophy induction through pharmacological intervention rather than surgical or mechanical methods, thereby reducing procedural complexity and invasiveness

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Reliability

If dexamethasone is used to induce muscular atrophy, then protein degradation pathways are activated, but the side effects and limitations of steroid-based treatment increase

Engineering Contradiction:

Improveactivation of proteolytic signaling pathwayVSAvoidside effects of steroid treatment

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent changes the chemical parameter of the treatment by using non-steroidal hypometabolism-inducing substances (T1AM, DADLE, 5'-AMP, H2S) that activate the same FoxO-proteasome proteolytic signaling pathway as dexamethasone but through different molecular mechanisms, thereby maintaining effective atrophy induction while avoiding the harmful side effects associated with long-term steroid use

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The use of these hypometabolism-inducing substances effectively induces muscular atrophy by activating degradation pathways and inhibiting synthesis, providing a viable model for drug screening and treatment of muscular atrophy and hypertrophy, including myostatin-related conditions.

Implementation Method 1

activates a proteolytic signaling pathway of FoxO-proteasome to induce the muscular atrophy

Methodology Applied

Scientific EffectProteasome degradation:

Implementation Method 2

3-iodothyronamine (T1AM) is a derivative of thyroid hormones T3 and T4 and a hypometabolism-inducing substance

Methodology Applied

Scientific EffectHypometabolism induction:

Data Source

PatentUS10821086B2Muscular atrophy-inducing agent using hypometabolism-inducing substance T1AM, and use thereof in treating muscular hypertrophy

Publication Date: 2020.11.03 YONSEI UNIV WONJU IND ACADEMIC COOP FOUND

AI summary

The present invention relates to: a muscular atrophy-inducing agent containing, as an active ingredient, a hypometabolism-inducing substance selected from the group consisting of 3-iodothyronamine (T1AM), [D-Ala2,D-Leu5] enkephalin (DADLE), 5′-adenosine monophosphate (5′-AMP), and hydrogen sulfide (H2S); a method for preparing a muscular atrophy study model comprising inducing muscular atrophy by administering the muscular atrophy-inducing agent; a study model prepared by the method; a screening method for a drug for preventing or treating muscular atrophy using the same; a composition for preventing or treating muscular hypertrophy; and a composition for facial muscle shrinkage. The muscular atrophy study model according to the present invention can provide a study model for an economic muscular atrophy study by using a hypometabolism-inducing substance which can be mass-produced, has an effect which may be usefully used by verification for screening of a drug for preventing or treating muscular atrophy, and can be usefully used as a compositions for preventing or treating muscular hypertrophy and a composition for facial muscle shrinkage through the muscular atrophy effect.